Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Maio Michele; Scherpereel Arnaud; Calabro Luana; Aerts Joachim; Cedres Perez Susana; Bearz Alessandra; Nackaerts Kristiaan; Fennell Dean A.; Kowalski Dariusz; Tsao Anne S.; Taylor Paul; Grosso Federica; Antonia Scott J.; Nowak Anna K.; Taboada Maria; Puglisi Martina; Stockman Paul K.; Kindler Hedy L.

首页> 外文期刊>The lancet oncology >Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

【24h】

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

机译：Tremetimumab作为二线或第三线治疗复发的恶性间皮瘤（确定）：多期，国际，随机，双盲，安慰剂控制第2B阶段试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.

机译：背景技术迫切需要新的恶性间皮瘤的疗效策略。在测定的研究中，我们研究了细胞毒性-T淋巴细胞相关抗原4（CTLA-4）单克隆抗体Tremetimimab在先前治疗的晚期恶性间皮瘤患者中的影响。

著录项

来源
《The lancet oncology》 |2017年第9期|共13页
作者
Maio Michele; Scherpereel Arnaud; Calabro Luana; Aerts Joachim; Cedres Perez Susana; Bearz Alessandra; Nackaerts Kristiaan; Fennell Dean A.; Kowalski Dariusz; Tsao Anne S.; Taylor Paul; Grosso Federica; Antonia Scott J.; Nowak Anna K.; Taboada Maria; Puglisi Martina; Stockman Paul K.; Kindler Hedy L.;
展开▼
作者单位

Univ Hosp Siena Ist Toscano Tumori Ctr Immunooncol Med Oncol &

Immunotherapy I-53100 Siena;

Univ Lille CHU Lille Pulm &

Thorac Oncol Lille France;

Univ Hosp Siena Ist Toscano Tumori Ctr Immunooncol Med Oncol &

Immunotherapy I-53100 Siena;

Erasmus MC Rotterdam Netherlands;

Vall dHebron Inst Oncol Barcelona Spain;

Ctr Riferimento Oncol Aviano Pordenone Italy;

Univ Leuven KU Leuven Univ Hosp Leuven Belgium;

Univ Hosp Leicester Leicester Leics England;

Maria Sklodowska Curie Inst Oncol Warsaw Poland;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Hosp South Manchester Manchester Lancs England;

SS Antonio &

Biagio Gen Hosp Dept Med Oncol Mesothelioma Unit Alessandria Italy;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

Univ Western Australia Sch Med &

Pharmacol Perth WA Australia;

AstraZeneca Alderley Pk Macclesfield Cheshire England;

AstraZeneca Cambridge England;

AstraZeneca Alderley Pk Macclesfield Cheshire England;

Univ Chicago Dept Med 5841 S Maryland Ave Chicago IL 60637 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial [J] . Maio Michele, Scherpereel Arnaud, Calabro Luana, The lancet oncology . 2017,第9期

机译：Tremetimumab作为二线或第三线治疗复发的恶性间皮瘤（确定）：多期，国际，随机，双盲，安慰剂控制第2B阶段试验
2. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial [J] . Ghanima Waleed, Khelif Abderrahim, Waage Anders, The Lancet . 2015,第9978期

机译：Rituximab作为成人免疫血小板减少症的二线治疗（Ritp试验）：多期，随机，双盲，安慰剂对照试验
3. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial [J] . Ghanima Waleed, Khelif Abderrahim, Waage Anders, The Lancet . 2015,第9978期

机译：利妥昔单抗作为成人免疫性血小板减少症的二线治疗（RITP试验）：一项多中心，随机，双盲，安慰剂对照试验
4. International Multi-Institutional Bench Mark Study on Dosimetric and Volumetric Modulation Using Helical TomoTherapy Treatment Planning for Malignant Pleural Mesothelioma Tumors [C] . Allen Movahed, Tommy Knoos, Claire Foottit World Congress on Medical Physics and Biomedical Engineering . 2015

机译：利用螺旋清热治疗规划对恶性胸膜间皮瘤肿瘤的螺旋清热治疗规划的螺旋疗法治疗规划的国际多机构长凳标记研究
5. A Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Effect of Intranasal Insulin on Cognition and Emotional Processing in Individuals with Treatment-Resistant Major Depressive Disorder. [D] . Cha, Danielle Soh-Young. 2016

机译：一项随机，双盲，安慰剂对照的交叉试验评估了鼻内胰岛素对难治性重度抑郁症患者认知和情绪加工的影响。
6. CONFIRM: a double-blind placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial [O] . Dean A. Fennell, Emma Kirkpatrick, Kelly Cozens, 2018

机译：确认：一项双盲安慰剂对照的III期临床试验研究了nivolumab在复发性间皮瘤患者中的作用：一项随机对照试验的研究方案
7. A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma [O] . 2013

机译：tremelimumab用于不可切除胸膜或腹膜间皮瘤患者二线和三线治疗的2期随机，双盲，安慰剂对照研究

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

摘要

著录项

相似文献

相关主题

期刊订阅